Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86097 trials found · Page 65 of 4305
-
New CAR-T battle plan tested against tough childhood leukemia
Disease control Recruiting nowThis is a multi-center, open-label, non-randomized, two-arm, non-inferior trial. Patients with r/r B-ALL would be assigned to the CD19 CAR and CD22 CAR T-cell sequential infusion group (Sequential CAR, Arm-1) and the CD19 CAR T-cell infusion bridging to hematopoietic stem cell tr…
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Major trial launches to test powerful new combo against advanced lung cancer
Disease control Recruiting nowThe purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 15, 2026 16:16 UTC
-
Brain cancer trial aims to boost radiation without extra harm
Disease control Recruiting nowGlioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multic…
Phase: PHASE2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
Major trial tests promising new combo against deadly lung cancer
Disease control Recruiting nowNon-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination wi…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 13, 2026 20:23 UTC
-
Emergency rooms launch new lifeline for black youth in suicide crisis
Prevention Recruiting nowThe overall goal of this study is to respond to the urgent need for an effective suicide prevention strategy for Black youth by examining the effectiveness of a systems-level strategy to recognize and respond to suicide risk among Black adolescents who present to emergency depart…
Phase: NA • Sponsor: New York University • Aim: Prevention
Last updated Apr 20, 2026 16:14 UTC
-
Gene therapy vs. cochlear implants: which restores hearing better?
Disease control Recruiting nowThis cohort study aims to explore the trends and differences in multidimensional perceptual levels of patients after cochlear implants or gene therapy, as well as to comprehensively assess the efficacy of gene therapy for congenital deafness, thus providing a reference for making…
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Breakthrough trial tests powerful drug duo to keep blood cancer at bay
Disease control Recruiting nowThe goal of this clinical trial is to compare a maintenance therapy consisting of iberdomide and isatuximab with an iberdomide-only regimen. The trial is the subsequent maintenance therapy to GMMG-HD8/DSMM XIX trial for patients with newly-diagnosed multiple myeloma. Patients wit…
Phase: PHASE3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New hope for sickle cell patients blocked from transplants
Disease control Recruiting nowThis multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patient…
Phase: PHASE2 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC
-
Stroke patients see better recovery with early dual antiplatelet therapy
Disease control CompletedEarly antiplatelet therapy is promising for further improvement of functional prognosis on the basis of intravenous thrombolytic therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of…
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Apr 24, 2026 16:05 UTC
-
Smart immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThe goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors tha…
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Apr 25, 2026 02:57 UTC
-
Immune cells from your own tumor could fight cervical cancer
Disease control Recruiting nowThis is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.
Phase: PHASE2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC
-
Two-Year brain drug trial seeks to slow Alzheimer's decline
Disease control OngoingThis study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
Phase: PHASE3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Gentler treatment tested for tough adult leukemia
Disease control Recruiting nowIn the treatment of Ph-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL) among adult patients, therapeutic outcomes remain suboptimal despite advances in chemotherapy and immunotherapy. A subset of adults with Ph- B-ALL have comorbidities or physiological limitations tha…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New hope for stroke patients: clot removal may beat meds alone
Disease control Recruiting nowA phase III, randomized, multi-center, investigational, open label clinical trial that will examine whether treatment with endovascular thrombectomy is superior to standard medical therapy alone in patients who suffer a Distal Medium Vessel Occlusion Ischemic Stroke within 12 hou…
Phase: NA • Sponsor: Raul Nogueira • Aim: Disease control
Last updated Apr 25, 2026 02:58 UTC
-
Massive infant study tests One-Shot RSV shield
Prevention CompletedThe primary objectives of the study are: To estimate the effectiveness of nirsevimab against polymerase chain reaction (PCR)-confirmed RSV (1) lower respiratory tract (LRTD) and (2) related medical encounters. the secondary objectives are: 1. To estimate the effectiveness of ni…
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Apr 09, 2026 19:34 UTC
-
New injection aims to stop dangerous bleeds in hemophilia patients
Disease control OngoingThe purpose of this study is to show that KN057 can prevent bleeds in patients with haemophilia A or B without inhibitors and is safe to use. Participants receiving on-demand treatment prior to screening will be randomly assigned to Experimental group or Control group at a ratio …
Phase: PHASE3 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
Major dengue vaccine trial seeks to protect millions from Mosquito-Borne virus
⭐️ VACCINE ⭐️ CompletedThe main aims of the study are to learn about side effects and a participant's immune response to Takeda's Dengue Vaccine when given twice within 3 months. Participants will receive 2 doses of their randomized treatment (vaccine or placebo). Children, teenagers and adults will r…
Phase: PHASE3 • Sponsor: Takeda • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 20, 2026 16:15 UTC
-
New Two-Drug combo trial offers hope for advanced lung cancer patients
Disease control OngoingThis is a Phase II/III, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with toripalimab, toripalimab monotherapy, and pembrolizumab monotherapy in patients with previously untreated locally advanced unresectable or metasta…
Phase: PHASE2, PHASE3 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New combo therapy aims to shrink rectal tumors, spare patients surgery
Disease control Recruiting nowTORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1). Group A receives 6 cycles of Toripalimab combined wit…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Apr 06, 2026 14:19 UTC
-
Ice in the nose to save the brain: race against time after cardiac arrest
Disease control Recruiting nowThe aim of this clinical trial is to study the impact of ultra-early transnasal evaporative cooling after cardiac arrest and subsequent hypothermia at hospital, on survival with complete neurologic recovery, compared to currently recommended normothermia. The study population wil…
Phase: NA • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Apr 15, 2026 16:16 UTC